AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM in cell-free assays. It is less potent to CDK5/6 and also inhibits GSK3β. Phase 1.

Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

AZD5438 Chemical Structure

AZD5438 Chemical Structure
Molecular Weight: 371.46

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

AZD5438 is available in the following compound libraries:

CDK Inhibitors with Unique Features

  • Selective CDK Inhibitors

    BS-181 HCl CDK7-selective, IC50=21 nM. SNS-032 (BMS-387032) CDK2-selective, IC50=48 nM.

  • Most Potent CDK Inhibitor

    LY2835219 CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Palbociclib (PD0332991) Isethionate Phase III for Metastatic Breast Cancer.

  • Newest CDK Inhibitor

    NU6027 Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Product Information

  • Compare CDK Inhibitors
    Compare CDK Products
  • Research Area

Product Description

Biological Activity

Description AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM in cell-free assays. It is less potent to CDK5/6 and also inhibits GSK3β. Phase 1.
Targets CDK2 [1]
(Cell-free assay)
CDK1 [1]
(Cell-free assay)
CDK9 [1]
(Cell-free assay)
IC50 6 nM 16 nM 20 nM
In vitro AZD5438 exhibits the potent inhibitory effect on activity of cyclin-dependent kinases including cyclin E-cdk2, cyclin A-cdk2, cyclin B1-cdk1, cyclin D3-cdk6, and cyclin T-cdk9 with IC50 of 6 nM, 45 nM, 16 nM, 21 nM, and 20 nM, respectively. Besides, AZD5438 also inhibits the kinase activity of p25-cdk5 and glycogen synthase kinase 3β with IC50 of 14 nM and 17 nM, respectively. [1] AZD5438 induces cell cycle arrest by inhibiting phosphorylation of cdk-dependent substrates, and exhibits the broad antiproliferative activity against a range of tumor cell lines including lung, colorectal, breast, prostate, and hematologic tumors with IC50 ranging from 0.2 μM (MCF-7) to 1.7 μM (ARH-77). [1]
In vivo In vivo, oral treatment of AZD5438 leads to statistically significant inhibition against the growth of human tumor xenografts derived from a wide range of different cancer types including breast, colon, lung, prostate, and ovarian with maximum TGI ranging from 38% to 153%. [1] In the SW620 xenograft model, AZD5438 causes the inhibition of several cell cycle proteins such as, phH3, phosphonucleolin, PP1a, and several phospho-pRb epitopes in a dose-dependent manner. [1]
Features A potent inhibitor of cyclin-dependent kinase (CDK) 1, 2, and 9.

Protocol(Only for Reference)

Kinase Assay: [1]

Recombinant Kinase Assays [1] The ability of AZD5438 to inhibit cdk activity is examined using a scintillation proximity assay with recombinant cdk-cyclin complexes of cyclin-Ecdk2, cdk2-cyclin A, cdk4-cyclin D, and recombinant retinoblastoma substrate (amino acids 792-928) or cdk1-cyclin B1 with a peptide substrate derived from the in vitro p34cdc2 phosphorylation site of histone H1 (biotin-X-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu). The activity of AZD5438 against recombinant cdk5/p25 (at 2 μM ATP) is determined in a scintillation proximity assay-based assay using peptide substrate (AKKPKTPKKAKKLOH). Inhibition of glycogen synthase kinase 3β activity is determined with scintillation proximity assay based on the use of human purified glycogen synthase kinase 3βenzyme and eukaryotic initiation factor 2B substrate (at 1 μM ATP). AZD5438 is screened against active recombinant human cdk6-cyclin D3, cdk7-cyclin H/MAT1 (cdk activating kinase complex), and cdk9-cyclin T using the kinase selectivity screening service.

Cell Assay: [1]

Cell lines MCF-7, HCT-116, A549, and IM-9
Concentrations 0 to 10 μM
Incubation Time 48 hours or 72 hours
Method AZD5438 is tested against solid tumor cell lines. Briefly, cells are incubated for 48 hours with AZD5438 at a range of concentrations. At the end of incubation, the cells are pulsed with 5-bromo-2′-deoxyuridine (BrdUrd) and the amount of DNA synthesis is measured. The IC50 for inhibition of proliferation is specifically determined independently of cell death. Multiple myeloma cell lines are seeded into 96-well plates in RPMI 1640 supplemented with 10% FCS and glutamine and dosed with AZD5438 for 72 hours. Cell growth is measured using AlamarBlue and GI50 values are calculated with reference to pretreatment control values.

Animal Study: [1]

Animal Models MCF-7, HCT-116, A549, and IM-9 cells are injected s.c. into the Swiss nude mice and nude rats.
Formulation AZD5438 is dissolved in hydroxy-propyl-methyl-cellulose.
Dosages ≤100 mg/kg
Administration Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Byth KF, et al. Mol Cancer Ther. 2009, 8(7), 1856-1866.

Clinical Trial Information( data from, updated on 2015-09-19)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT00088790 Completed Neoplasms AstraZeneca July 2004 Phase 1
NCT00088790 Completed Neoplasms AstraZeneca July 2004 Phase 1

Chemical Information

Download AZD5438 SDF
Molecular Weight (MW) 371.46


CAS No. 602306-29-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 74 mg/mL (199.21 mM)
Ethanol 74 mg/mL (199.21 mM)
Water <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine

Customer Product Validation (4)

Click to enlarge
Source Nat Commun 2014 5, 3561. AZD5438 purchased from Selleck
Method IP-Western
Cell Lines HEK-293 cells
Concentrations 2 uM
Incubation Time
Results Phosphorylation of EXO1 in cells synchronized in G2 was attenuated by the CDK inhibitors AZD5438 and Roscovitine, both of which inhibit CDKs 1 and 2, the principal CDKs driving progression through S and G2 phases.

Click to enlarge
Source Mol Cancer Ther 2014 13(3), 662-74. AZD5438 purchased from Selleck
Method Western blot
Cell Lines J558 cells
Concentrations 0.2-4 umol/L
Incubation Time 6 h
Results J558 cells treated with the relatively specific CDK1 inhibitors RO3306, AZD5438, or JNJ-7706621 for 6 hours exhibited significantly reduced XBP-1s expression.

Click to enlarge
Source Antimicrob Agents Chemother 2014 58(8), 4486-94. AZD5438 purchased from Selleck
Method Western blot
Cell Lines sensitizes L. monocytogenes cells
Concentrations 0-50 uM
Incubation Time 12 h
Results To determine if the mechanism of action is similar to that of staurosporine, we analyzed the ability of AZD5438 to inhibit PrkA and Lmo0618 activities in a biochemical phosphorylation assay. Similarly to staurosporine, we observed that AZD5438 specifically inhibits PrkA while not inhibiting Lmo0618. A higher-resolution dose-response curve shows both autophosphorylation and substrate phosphorylation being inhibited in a dose-dependent manner in treating with AZD5438.

Click to enlarge
Source Helen Sadik from Johhns Hopkins University. AZD5438 purchased from Selleck
Method MTT
Cell Lines MCF10A-Ras,MDA-MB-231, SUM159, MCF-7 cells
Incubation Time 24 h
Results Different breast cancer cell lines were seeded in 96 well plates and treated with different concentrations of AZD5438. After 72h, cell viability was assessed by MTT. Data shows that these cancer cell lines were sensitive to CDK1/2/9 inhibition, however the most aggressive (SUM159 and MDA-MB-231) cells were less susceptible.

Product Use Citation (4)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CDK Products

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD-0332991) HCl

    Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol (Alvocidib) HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • LY2835219

    LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

Recently Viewed Items

Tags: buy AZD5438 | AZD5438 supplier | purchase AZD5438 | AZD5438 cost | AZD5438 manufacturer | order AZD5438 | AZD5438 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us